SNODGRASS H. RALPH 4
4 · VistaGen Therapeutics, Inc. · Filed Mar 14, 2019
Insider Transaction Report
Form 4
SNODGRASS H. RALPH
DirectorPRES./CHIEF SCIENTIFIC OFFICER
Transactions
- Exercise/Conversion
Common Stock
2019-03-13$1.50/sh+2,500$3,750→ 62,724 total - Exercise/Conversion
Stock Option (Right to Buy)
2019-03-13−2,500→ 0 totalExercise: $1.50From: 2013-03-24Exp: 2019-03-24→ Common Stock (2,500 underlying)